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Abstract
Cryptococcus neoformans (Cn) is a significant human pathogen that, despite current treatments, continues to have a high
morbidity rate especially in sub-Saharan Africa. The need for more tolerable and specific therapies has been clearly shown.
In the search for novel drug targets, the gene for glucosylceramide synthase (GCS1) was deleted in Cn, resulting in a strain
(Dgcs1) that does not produce glucosylceramide (GlcCer) and is avirulent in mouse models of infection. To understand the
biology behind the connection between virulence and GlcCer, the production and localization of GlcCer must be
characterized in conditions that are prohibitive to the growth of Dgcs1 (neutral pH and high CO2). These prohibitive
conditions are physiologically similar to those found in the extracellular spaces of the lung during infection. Here, using
immunofluorescence, we have shown that GlcCer localization to the cell surface is significantly increased during growth in
these conditions and during infection. We further seek to exploit this localization by treatment with Cerezyme (Cz), a
recombinant enzyme that metabolizes GlcCer, as a potential treatment for Cn. Cz treatment was found to reduce the
amount of GlcCer in vitro, in cultures, and in Cn cells inhabiting the mouse lung. Treatment with Cz induced a membrane
integrity defect in wild type Cn cells similar to Dgcs1. Cz treatment also reduced the in vitro growth of Cn in a dose and
condition dependent manner. Finally, Cz treatment was shown to have a protective effect on survival in mice infected with
Cn. Taken together, these studies have established the legitimacy of targeting the GlcCer and other related sphingolipid
systems in the development of novel therapeutics.
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Introduction
Cryptococcus neoformans (Cn) is one of the major fungal human
pathogens and continues to have clinical significance despite the
development of antifungal drugs. Typically, Cn is an opportunistic
pathogen causing a significant disease in immunocompromised
patients [1], and it has been shown to cause serious pulmonary
infections in individuals with fully functioning immune systems
[2]. The initial portal of infection in humans is through the lung,
when spores or desiccated yeast cells are inhaled from
environmental reservoirs such as pigeon droppings [2]. Within
the lung, Cn acts as a facultative intracellular pathogen, growing
in either the extracellular spaces of the alveoli or intracellularly in
the acidic phagolysosome of the alveolar macrophages. In some
patients, this infection progresses, disseminating to the blood-
stream where it can cause infections in most major organ systems.
The most clinically important aspect of this process is when Cn
enters the central nervous system (CNS), where it thrives,
becoming the most common cause of fungal meningoencephalitis
in the world. The Center of Disease Control and Prevention
(CDC) estimates that over 1 million new cases/year of
cryptococcosis are reported worldwide in patients with acquired
immune deficiency syndrome (AIDS), with over half those
affected dying of the infection, making deaths caused by
cryptococcosis in patients with HIV in sub-Saharan Africa more
frequent than deaths caused by tuberculosis [3,4]. This is drastic
increase considering that prior to the mid-1950s, fewer than 300
cases of cryptococcosis had been reported in the medical
literature (reviewed in [5]). Thus, studies looking at new
treatment strategies are needed.
Understanding the pathophysiology of Cn is crucial to the
development of proper treatments. Current clinical standard for
Cn involves amphotericin B plus 5-fluorocytosine but problems
with tolerance of their side effect combined with the existence of
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resistant strains has led to an ongoing search for more tolerable
and efficacious drug treatments.
The general characteristics of an ideal drug target for a pathogen
would be one that targets the biology of the microbe with little to no
effect on the host. For these reasons, one growing field of study in
clinically related microbiology is the sphingolipid pathways of the
organism of interest. Fungal sphingolipid pathways are distinct in
many ways from their mammalian analogs, both in the enzymes
and products involved. The sphingolipid biosynthetic pathway has
been implicated in the growth and virulence of several clinically
significant fungi (reviewed in [6,7,8,9]), the best studied of these
being Cn [10,11,12,13,14,15,16].
Of note, glucosylceramide synthase (Gcs1) has been implicated in
the growth cycle of Aspergillus [17] and directly linked to virulence in
Cn [18]. The deletion of the gene encoding this enzyme in Cn results
in a strain (Dgcs1) that does not cause morbidity or mortality in
inhalation mouse models of cryptococcosis. Instead, these cells are
contained within granulomatous structures in the lung. Interesting-
ly, the same strain (Dgcs1) shows comparable mortality to wild type
when introduced intravenously. This suggests that GlcCer and the
ability to grow extracellularly are crucial to virulence early in the
process of infection and dissemination. Further investigation of this
phenotype reveals that Dgcs1 has in vitro deficits in growth at
conditions found in the extracellular spaces of the lung (5% CO2
and pH 7.4). Dgcs1 therefore has growth characteristics similar to an
obligate intracellular pathogen, because it is still able to grow at the
low pH (4.0) found in the macrophage’s phagolysosome.
The various functions of glucosylceramide (GlcCer) in several
fungi and plants are still being studied [19,20]. The presence of
GlcCer in fungi has been associated with the ability to grow at
more alkaline pH [21]. GlcCer is known to localize to the cell
surface in Cn, particularly at sites where daughter cells are budding
from the mother [22]. GlcCer also is found in Cn in vesicles
secreted through the cell wall to the extracellular space [23,24]
that contain polysaccharides used in the synthesis of the capsule.
Patients with cryptococcosis elicit an antibody response against
glucosylceramide [25]. Some studies have suggested that GlcCer
may be a good target for antifungal therapies. Antibodies isolated
from these patients have both shown to inhibit the growth of Cn in
vitro [22]. Using anti-GlcCer antibodies in passive immunization of
mice infected with Cn showed a protective effect [26]. Taken
together, these studies suggest that Gcs1 and/or its product,
GlcCer, would be ideal targets for potential anti-cryptococcal
therapies. To date, no specific inhibitors for fungal Gcs1 exist.
Inhibitors of the mammalian homolog have no significant effect on
the cryptococcal enzyme (unpublished Del Poeta data).
The purpose of this work is to characterize the role of GlcCer in the
conditions where the Dgcs1 strain fails to thrive and to evaluate the
potential of targeting GlcCer pharmacologically as an anti-crypto-
coccal therapy. Human patients with Gaucher’s disease have genetic
defects in the catabolism of GlcCer. As a therapy for this disease, a
human recombinant GlcCer glucosidase called Cerezyme (Cz) is
given exogenously. This enzyme hydrolyzes the glucose moiety from
the first carbon position of the GlcCer molecule, yielding glucose and
ceramide. Here we report the investigation of the behavior of GlcCer
in Cn biology during infection and the exploitation of this
glycosphingolipid as a potential therapy for Cn infection.
Results
Production of IgM monoclonal antibodies against Cn
GlcCer
Using the hybridoma technique described in the Materials and
Methods, several IgM clones were obtained and two clones (IgM-
B11 and IgM-F09) were chosen for further studies. IgM-B11
contains a kappa light chain whereas IgM-F09 contains a lambda
light chain. Using ELISAs, illustrated in the Figure 1, both IgM-
B11 and IgM-F09 antibodies reacted with GlcCer isolated from
Cn, Ca, and soy but not with human GlcCer. Neither IgM-F09 nor
IgM-B11 reacted with mouse GlcCer. To make sure that the
antibodies are specifically directed to GlcCer and not to the
ceramide back bone, we tested whether these antibodies would
react with different species of ceramides, fatty acids, or with a
ceramide harboring a different sugar moiety, such as galactosyl-
ceramide (GalCer) and found no interaction (Figure 1), confirming
that the b-glucose unit is essential for the binding of both IgM-B11
and IgM-F09 antibody to GlcCer. Thus, these antibodies were
used for the studies indicated below.
GlcCer localizes to the cell surface of Cn during intranasal
infection
Previous studies have shown that GlcCer localizes at the surface
of the cell during infection. Additionally, Dgcs1 strain lacking
GlcCer shows impaired ability to grow on media supplemented
with sodium dodecyl sulfate (SDS), a detergent that affects fungal
membranes. Suggesting a possible role of GlcCer in membrane
stability, we examined the localization of GlcCer at conditions that
are restrictive or permissive to growth of the Dgcs1 strain. Using
indirect immunofluorescence with the IgM F09 monoclonal anti-
Cn GlcCer antibody as a primary produced in our laboratory
(please see Materials and Methods). GlcCer signals were assessed
using cells grown overnight at high CO2 in minimal media in
either pH 4.0 (Figure 2A) or 7.2 (Figure 2B). These are presented
here as merged fluorescence and light microscope images. The
number of surface puncta per cell were counted in three separate
fields of at least 75 cells total (Figure 2C) and averaged from three
separate experiments. The Cn cells grown in minimal media at
pH 7.2 showed a significant increase in surface puncta per cell
compared to those grown in pH 4.0. These growth conditions
mimic those seen in the extracellular spaces of the lung during
infection, and therefore we hypothesize that this increased surface
localization would be seen in cells taken from infection models. To
confirm this, mice were infected with Cn for 48 hours, and the cells
were removed by BAL procedure. These cells were subjected to
the same indirect immunofluorescence protocol as above
(Figure 3A and 3B) and surface puncta were quantified
(Figure 3C). The cells taken ex vivo from murine infection models
showed a similar pattern of GlcCer surface localization as those
grown in the in vitro conditions used to mimic the physiological
conditions seen in extracellular space of the lung. In all these
experiments, negative controls with the Dgcs1 strain and with WT
Cn incubated with only secondary antibody were used, and showed
no appreciable immunofluorescence signal (data not shown).
One potential confounding variable in this scenario is the
capsule size. To determine if this same differential localization
occurs in an acapsular strain, Dcap59, flow cytometry was used,
using the monoclonal IgM F09 anti-Cn GlcCer antibody as the
primary (Figure 4). Even in the acapsular strain, the amount of
GlcCer available on the surface for flow cytometry was increased
significantly in the strain when grown at pH 7.2 as compared to
growth at pH 4.0. This suggests that the localization observed by
indirect immunofluorescence is not due to differences in capsule
size during growth in these conditions. Immunofluorescence
protocols with Dcap59 were attempted, however separation of
the cells from each other after fixation was difficult and low-yield.
Using the flow cytometry protocol, separation was greatly
improved and clumped cells could be excluded from analysis.
Cerezyme as an Antifungal
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Increased GlcCer on cell surface is not a result of
increased expression, enzyme activity, production, or
reduced degradation in conditions seen in the lung
during infection
The increased localization of GlcCer to the cell surface upon
growth in conditions of high CO2 and neutral/alkaline pH could
be explained by biological changes due to an increased production
or/and to an increased trafficking of GlcCer. To discern between
the two possibilities, several scenarios should be considered. For
one, increased expression of GCS1 during these conditions could
explain this increased surface GlcCer localization. To test this,
reverse transcription PCR was performed on cells grown in the
permissive and the restrictive conditions using primers specific to
the cryptococcal GCS1 gene. The forward and reverse primers
bind different exons, so that the transcript from cDNA template
would be distinct in size from the transcript of any contaminating
genomic DNA (gDNA). There were no apparent differences in the
amount of transcript seen using this technique from Cn grown at
neutral/alkaline compared to those from acidic pH (Figure S1).
Another possibility is that the Gcs1 enzyme itself has a higher
activity rate when grown at the more neutral/alkaline pH of 7.2–
7.4. This must be tested for both in vitro activity and in vivo
production. In vitro activity assays for GlcCer synthase in fungi
have been reported [27], however these techniques did not work
for Cn in our hands, and had to be adapted for these purposes.
Using the technique described here, the in vitro activity of Gcs1 in
Cn was determined using different substrates (Figure 5A and 5B).
Ceramide species used as substrates in this assay were either R or S
isomers, with respect to the a-OH group on the acyl chain.
Membranes containing human GCS enzyme and wild type Cn
Gcs1, as well as membranes from the reconstituted Cn strain
(Dgcs1REC) and the Dgcs1 were tested for in vitro Gcs1 activity.
While the human enzyme appears to be able to use both R- (the
natural conformation) and the S- (a synthetic conformation)
isomers of ceramide as a substrate, the Gcs1 from Cn showed
substrate specificity for the naturally occurring isomer. The
membranes from the Dgcs1 strain showed no activity. Once
established, this assay was used to determine if differences in
enzyme activity exist between membranes from Cn grown at
pH 7.2 in either high (5%) or low (0.04%) CO2 (Figure 5C). Note
that whereas the CO2 concentration was varied in this experiment,
the pH chosen (7.2) still allowed this to be a comparison of
conditions which are prohibitive (pH 7.2, high CO2) and
permissive (pH 7.2, low CO2) to Dgcs1 growth. This was done
for this assay alone because in vitro assays are sensitive to pH
changes. After quantification of radiolabeled GlcCer, the in vitro
activity of Gcs1 showed no significant differences when cells were
grown at either high or low CO2. These in vitro examinations of
Gcs1 activity do not provide information with regards to the
production of GlcCer in living Cn cells. To assess this parameter
fully, an in vivo assay of GlcCer production was performed by
adding a radiolabelled palmitate, which will be incorporated in
ceramide and, thus in GlcCer. At several time points ranging from
short term to stationary phase of growth, production of GlcCer
was determined in Cn grown in minimal media at 5% CO2 in
either neutral (7.2) or acidic (4.0) pH. Across all time points
examined, there was no significant difference in in vivo production
of GlcCer when grown at these time points (Figure 6). GlcCer
degradation was also examined in these conditions using a similar
assay with a pulse-chase experimental design. This degradation
rate showed no differences in cells grown at pH 4.0 compared to
pH 7.2 (Figure 7).
These examinations of in vivo production of GlcCer in culture
only take into account the amount produced during specific time
points tested, but it does not provide information on the total mass
of GlcCer. To address this, the total lipids were extracted from
cultures of wild type (Figure S2A) and Dcap59 (Figure S2B) grown
at various time points at 5% CO2 in either pH 4.0 or 7.2. These
lipids were subjected to mass spectroscopy to quantify the amount
of fungal GlcCer, normalized to cell number. There were no
significant differences in the total amount of GlcCer from Cn
grown at pH 4.0 compared to pH 7.2 at any of the time points
examined. Taken together, these studies suggest that the
differences in surface localization of GlcCer during infection and
growth at infection-like in vitro conditions may be due to and
increased trafficking of GlcCer to the surface and not to an
Figure 1. Specificity of IgM anti-GlcCer monoclonal antibody.
Monoclonal IgM-B11 and F09 antibody recognize Cryptococcus neofor-
mans (Cn)-, Candida albicans (Ca)- and soy-GlcCer but not mouse (Ms)-
GlcCer, human (Hu) GlcCer, galactosylceramide (GalCer), 2-hydroxy-
C16:0 fatty acid, 3-hydroxy-C16:0 fatty acid, S’-hydroxy-C16 ceramide
(Cer) or R’-hydroxy-C16 Cer. Approximately, 5 mg of each lipid were
used in the assay.
doi:10.1371/journal.pone.0015572.g001
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increased synthesis. Please note that intracellular cytosolic GlcCer
is not visualized with our methods because cells are not
permeabilized with Triton X and, thus, IgM F09 primary does
not enter the cell. This fixation-based method was preferred to
avoid a possible mis-localization or redistribution of GlcCer from
the surface during the experiment.
Figure 2. Localization of GlcCer in Cn grown in vitro at high CO2 and either acidic or neutral pH. Indirect immunofluorescence was used
to determine the localization of GlcCer in wild type Cn in media of either acidic (A) or neutral (B) pH. Primary antibody used is an anti-Cn GlcCer
monoclonal antibody developed by our lab. The secondary was an isotype-specific FITC-conjugated antibody, and confocal microscopy was used to
analyze the images. The amount of surface puncta per cell was quantified by counting puncta from three large fields of cells, averaged by cell
number (C).
doi:10.1371/journal.pone.0015572.g002
Figure 3. Localization of GlcCer in Cn during infection. Wild type mice were infected with 56107 cells of H99 and allowed to incubate for
48 hours. The cells were then removed from the lungs of the mice by broncheoalveolar lavage (BAL). Indirect immunofluorescence was used to
determine the localization of GlcCer in wild type Cn in the inoculum used to infect (A) as compared to the cells recovered from the BAL (B). The
amount of surface puncta per cell was quantified by counting puncta from three large fields of cells, averaged by cell number (C).
doi:10.1371/journal.pone.0015572.g003
Cerezyme as an Antifungal
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Cz hydrolyzes fungal GlcCer in vitro
As mentioned above, the ultimate goal for studying pathways
crucial to virulence of fungi like Cn is to develop therapeutic
strategies that target these pathways. The phenotype of the Dgcs1
strain shows a critical role for the production of GlcCer in Cn
virulence. While targeting the fungal Gcs1 enzyme has, to date,
proven unsuccessful with existing inhibitors in Cn (unpublished Del
Poeta lab data), we hypothesize that targeting GlcCer directly
would be an effective way to recapitulate the Dgcs1 avirulent
phenotype in wild type Cn during infection. Previous experiments
here showing that GlcCer is localized to the cell surface during
conditions where the Dgcs1 strain shows growth defects further
suggest that targeting the GlcCer directly could have therapeutic
significance.
There are considerations to address before examining the
efficacy of targeting GlcCer in Cn. Structural differences exist
between the GlcCer species found in humans and in fungi [19,28].
Notable differences in the structure of fungal GlcCer include the
methylation at position 9 of the sphingoid backbone (Figure 8A),
compared to the human GlcCer (which does not have this
modification). To determine if Cz can effectively hydrolyze fungal
GlcCer in vitro, 8 mg of purified Cn GlcCer were incubated with
200 mU/mL of Cz for 1 hour at 37uC, then visualized on TLC
(Figure 8B) and later measured with mass spectroscopy (Figure 8C).
Treatment with Cz showed a significant decrease in the amount of
Cn GlcCer with a concomitant increase in 9-methyl-ceramide
(precursor to GlcCer synthesis), whereas PBS-treated showed no
hydrolysis (Figure 8B and 8C).
Cz hydrolyzes fungal GlcCer in growing cultures of Cn
Many features of Cn biology not seen in the previous in vitro
assay, including the polysaccharide capsule, could prove to be a
barrier to Cz’s use as a treatment. In order to potentially be used
as a therapy, it must be shown that Cz treatment is also able to
reduce the amount of GlcCer in growing cultures. Cultures of wild
type Cn and the Dgcs1 strain were treated with increasing amounts
of Cz for 1 hour at 37uC. The lipids were extracted and analyzed
for GlcCer content by mass spectroscopy (Figure 9). Cz treatment
of wild type Cn showed a dose-dependent decrease in GlcCer up to
200 mU/mL. Dgcs1 had no detectable GlcCer with or without Cz
treatment.
Cz treatment induces membrane integrity defects in wild
type Cn cells in vitro
Based on Dgcs1 phenotype (hypersensitivity to SDS), a potential
cause for the lack of viability in this strain is a defect in membrane
integrity. If Cz treatment recapitulates the Dgcs1 phenotype, as
hypothesized, treatment with this enzyme should induce a similar
membrane integrity defect. To test this, we used the fluorescent
dye SYTOX, which is excluded from functional membranes.
When SYTOX enters the cell, it can bind to nucleic acids, causing
it to fluoresce. Here we examine two dosages of Cz compared to
Figure 4. Amount of cells with GlcCer available on the cell
surface of Cn. The amount of GlcCer available on the surface of the Cn
was assessed in wild type and the acapsular Dcap59 strain using flow
cytometry. The cells were grown at either pH 7.2 (black bars) or 4.0
(white bars). These graphs represent the percentage of cells with
positive signal from APC-conjugated secondary antibodies bound to
anti-fungal GlcCer primary antibodies on the cell surface. There was
negligible signal from the Dgcs1 strain (negative control, subtracted as
background).
doi:10.1371/journal.pone.0015572.g004
Figure 5. In vitro assay of GCS activity in Cn. An in vitro assay for GCS activity in Cn was successfully adapted from previously described methods.
(A.) The bands from the thin layer chromatography corresponding to GlcCer (box) were quantified using a scintillation counter. The radioactive signal
was normalized to the total amount of protein (B). The activity of human GCS, wild type (WT) Cn, Dgcs1, and Dgcs1-reconstituted strains was assessed
using both the R and S isomers of the ceramide substrate. (C.) In vitro activity of WT Cn was evaluated at pH 7.2 and either high (5%) or low (0.04%)
CO2.
doi:10.1371/journal.pone.0015572.g005
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vehicle control on the WT Cn, Dcap59 (Figure 10A), and Dgcs1
strains (Figure 10B). Notice that the Dgcs1 strain shows a high
fluorescent signal, indicating a defect in its ability to exclude
SYTOX from the cell. While the magnitude is much lower, the
treatment with Cz induces a dose-dependent increase in SYTOX
signal in both WT Cn and Dcap59 strain.
Cz treatment reduces in vitro growth of Cn in high but
not low CO2
Now that Cz has proven to be effective in hydrolysis of fungal
GlcCer, the effect of Cz on the growth of Cn was determined. In
minimal media, 104 Cn cells were grown at pH 7.2 in either high
(Figure 11A) or low CO2 (Figure 11B). These conditions were
chosen because they were restrictive and permissive to the growth
of Dgcs1, respectively. Concentration of Cz ranged from zero (no
treatment) to 200 mU/mL. Figure 11 illustrates how concentra-
tions of Cz reduced the growth of Cn in vitro compared to no
treatment but only at 5% CO2, and not at 0.04% CO2.
Cz hydrolyzes fungal GlcCer from Cn during infection in
mouse models
For potential translation of this work into infection models, the
ability of Cz to hydrolyze GlcCer from Cn in the mouse lung was
assessed. Thus, mice were infected with 107 Cn cells intranasally.
Immediately after the inoculation of Cn cells, mice were given Cz
intranasally (either 10, 20, or 30 U/kg, or vehicle alone). Though
the dosage recommendations for Cz in humans varies, these
dosages used are within the parameters of those used in human
therapy. Mice were sacrificed at either 24 (Figure 12A) or 48 hours
(Figure 12B) and the fungal cells were removed from the lung by
broncheoalveolar lavage (BAL). After separation from alveolar
macrophages, the lipids were extracted from Cn cells and analyzed
by mass spectroscopy for fungal GlcCer content. Cz treatment
showed a dose-dependent decrease in this model as well, in both
24 and 48-hour time points.
Cz treatment significantly prolongs the life of mice in an
inhalation murine model of cryptococcosis
Finally, the effect of Cz on the virulence of Cn was evaluated.
We used the inhalation murine model of Cn infection that is both
widely used and clinically relevant. This model was also chosen
based on the phenotype of the Dgcs1 strain, which did not cause
meningoencephalitis when administered intranasally, highlighting
the fact that the role of GlcCer occurs in the lung infection. Thus,
mice were infected with 56105 Cn cells and treated 20 minutes
later with either vehicle (PBS), 20 U/kg, or 40 U/kg of Cz,
intranasally. These treatments were repeated every other day until
death. Their survival was monitored (Figure 13). While both
treatment groups showed a benefit with the administration of Cz,
the higher dose showed a highly significant increase in the lifespan
of the mice. The average post-infection day of death was 27.6 days
+/2 0.97 for vehicle alone (PBS), 31.4 days +/2 3.4 for 20 U/kg
of Cz, and 35.5 days +/2 2.4 for 40 U/kg of Cz. The 40 U/kg
dose showed significant increase in survival as determined by the
Wilcoxon Rank Sum Test (p,0.01) compared to vehicle alone.
Figure 7. In vivo degradation of GlcCer in Cn grown at high or
low CO2. To determine if these growth conditions affect the
degradation of GlcCer in vivo, a pulse of radiolabeled palmitate was
given to live cultures at either high or low CO2. Cells were collected at
set time points after the palmitate was removed and the amount of
GlcCer was analyzed on film from 1–72 hrs at 0.04% CO2 (A) and 5%
CO2 (B), then quantified with a scintillation counter (C). GlcCer showed
little or no degradation in either condition during the selected time
frames.
doi:10.1371/journal.pone.0015572.g007
Figure 6. In vivo production of GlcCer in Cn grown in high and
low CO2. To determine if in vivo GlcCer production is affected by CO2
concentration as seen in the Dgcs1 strain, wild type Cn was grown at
various time points (below), then given radiolabeled 3H-palmitate for
two hours. This in vivo assay shows the incorporation of 3H-palmitate
into more complex lipids, such as GlcCer. The lipids were extracted from
Cn grown at 0.04% (A) and 5% (B) CO2. Lipids were separated on TLC
before being exposed to film to visualize. The production was tested at
time points from 1–72 hours in the growth curve of Cn. These bands
were quantified for the amount of radioactive signal using a scintillation
counter, and normalized to inorganic phosphate (Pi) as a measure of
cell number (C).
doi:10.1371/journal.pone.0015572.g006
Cerezyme as an Antifungal
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Discussion
Previous studies have shown that glucosylceramide synthase is
essential for the pathogenicity of Cn [18]. Targeting this system,
therefore, has potential use in novel antifungal therapies. Past
attempts to use existing inhibitors of mammalian GlcCer synthase
revealed that they do not reduce the activity of the fungal enzyme
or affect the growth of Cn. However, studies targeting fungal
GlcCer using antibodies against it have been shown to have anti-
cryptococcal affects in vitro [22] and confer passive immunity to
mice infected with Cn [26]. In this study, we exploited fungal
GlcCer as a potential target.
First, we studied the localization of GlcCer and its production
during infection-like conditions and the effects of the enzymatic
degradation of fungal GlcCer on cryptococcal growth and
infection. Using immunofluorescence, we showed an increased
localization of GlcCer to the cell surface during infection. GlcCer
has been shown to be trafficked through the cell membrane, cell
wall, and into the extracellular environment in vesicles, so it is
possible that GlcCer could be found in any of these structures.
Next, we determined that this increase is a reflection of increased
trafficking to the membrane by excluding changes in Gcs1
expression or activity, GlcCer production or degradation, and
total GlcCer during growth at the conditions that mimic the
extracellular spaces of the lung environment. While many other
molecules in Cn may show differential trafficking during growth at
these conditions, GlcCer is of particular interest due to the
clinically relevant phenotype of conditional avirulence in the Dgcs1
mutant.
Despite this exclusionary data being negative per se, there are
still a few pieces of information about the biology and biochemistry
of Cn learned from these experiments. We adapted a reliable
biochemical assay for in vitro Gcs1 activity in Cn, which showed not
only a substrate specificity on the stereochemistry of the a-OH
group of the ceramide acyl chain, but can also be a surrogate
measurement for amount of Gcs1 at the membrane. Additionally,
whereas these studies showed no differences in GlcCer production
or degradation in living cultures of Cn, we show here that
palmitate radiolabeling is a reliable method for examining lipid
profiles of growing fungal cultures at various points in the growth
curve, and can also be used to examine lipid degradation. While
the specific localization (e.g. cell wall, capsule) cannot be
accurately assessed with the resolution provided by the immuno-
Figure 8. Treatment of fungal GlcCer in vitro with Cerezyme. A) Enzymatic reaction leading to the degradation of GlcCer in Cn catalyzed by
beta-glucosidase (Cerezyme). B) Extracted cryptococcal GlcCer (8 mg) was treated in vitro with 200 mU/ml of Cerezyme for 1 hour at 37uC. The
reaction was stopped, lipids extracted, and loaded on a TLC with a soy standard for GlcCer. The GlcCer was visualized with a resorcinol spray. C) The
same amount of GlcCer was treated with 200 mU/ml of Cerezyme and the amount of GlcCer was analyzed with mass spectrometry, along with the
amount of the reaction product, a-OH-D8-Me-Ceramide (Me-Ceramide). The GlcCer treated with Cerezyme showed complete hydrolysis in these
conditions.
doi:10.1371/journal.pone.0015572.g008
Figure 9. Cerezyme treatment effect on the amount of GlcCer
in cultures of Cn. Mass spectroscopy was used to analyze amount of
GlcCer of wild-type H99 or Dgcs1 mutant strain treated with different
concentrations of Cerezyme for 1 hour at 37uC normalized to
phosphate (Pi). Enzyme treatment hydrolyzed GlcCer in a dose-
dependent manner. *, P,0.05 by Student t test, WT 100 or 200 versus
untreated (2).
doi:10.1371/journal.pone.0015572.g009
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fluorescence alone, the increased localization to the surface during
infection makes the Cn GlcCer more vulnerable to external
enzymatic degradation.
To exploit this hypothesis, we used the recombinant human
enzyme, Cz, which hydrolyzes the glucose moiety of mammalian
GlcCer. We found that Cz degrades fungal GlcCer in vitro, in
cultures of Cn, and in Cn that reside in the mouse lung. These
experiments were needed in order to show the feasibility of using a
human enzyme on the similar yet distinct fungal GlcCer and also
to assess the plausibility of this enzyme being used in the context of
a mammalian host lung. Recall that human inhibitors of GlcCer
synthase do not affect the cryptococcal enzyme Gcs1. In terms of
substrate specificity, the human enzyme has been shown to
glycosylate many different substrates, while the cryptococcal
enzyme has a more narrow range of specificity [15]. Though Cz
(human glucocerebrosidase) is a distinct enzyme from human
GlcCer synthase, it is reasonable to assume that the catabolic
human enzyme, Cz, would also have to recognize multiple
substrates.
In the experiments from Figures 9 and 12 where actual Cn cells
are used, there seems to be a plateau in the ability of Cz to
hydrolyze GlcCer. One explanation for this is that these
experiments were conducted at the physiological pH found in
the extracellular spaces of the lung (7.2–7.4), whereas the optimum
pH for Cz activity is more acidic. This could have limited the
enzymatic activity of Cz at a protein level. Another possibility is
that Cn has a well-studied polysaccharide capsule that can act as a
barrier. This may account for the plateau in hydrolysis seen.
Finally, Cn is known to secrete several proteases [29]. These
enzymes may inactivate Cz to a point where increased
concentration will not correlate to increased activity.
To characterize the effects of Cz treatment on Cn biology, we
used the dye SYTOX, which fluoresces upon binding to nucleic
acids, but is excluded from functional membranes. We showed
that the membrane from the Dgcs1 strain has an impaired ability to
exclude SYTOX, indicating a membrane integrity deficit in this
strain. This is supported by the observation that the Dgcs1 has a
growth defect in media supplemented with SDS [18]. Indeed,
upon treatment with increasing concentrations of Cz, a dose-
dependent increase in membrane permeability to SYTOX in both
wild type Cn and Dcap59 strains was observed. Even at the
maximum dose examined, however, the degree of SYTOX signal
from Dgcs1 strain was higher than the Cz-treated strains (compare
CZ 0 in Figure 10B with WT Cz 400 in Figure 10A). This was
expected as Cz treatment does not hydrolyze all GlcCer, whereas
Figure 10. Cerezyme treatment reduces membrane integrity of
Cn. Membrane integrity is indirectly measured using a dye, SYTOX, that
fluoresces upon entering a cell, but is excluded from functional
membranes. This is measured in arbitrary units of fluorescence (with
background subtracted). The strains tested here were WT Cn and
Dcap59 (A) and Dgcs1 (B). WT and Dcap59 strains show increasing
fluorescence when treated with Cerezyme (0, 200 mU/ml, or 400 mU/
ml), but Dgcs1 remains unaffected by treatment. Dgcs1 also shows a
much higher signal than other strains. *, P,0.05 by Student t test, WT
200 mU/ml or 400 mU/ml versus untreated; #, P,0.05 by Student t
test, acapsular 200 mU/ml or 400 mU/ml versus untreated.
doi:10.1371/journal.pone.0015572.g010
Figure 11. Cerezyme treatment effect on the in vitro growth of Cn. In vitro growth of Cn was assessed in minimal media, pH 7.2, at either 5%
(A) or 0.04% (B) CO2 with different concentrations of Cerezyme (0, 50, 100 or 200 U/mL). Treatment shows a dose-dependent inhibition of fungal
growth. This growth reduction was not observed in the cells grown at low (0.04%) CO2. *, P,0.05 by Student t test, WT 50 mU/ml or 100 mU/ml or
200 mU/ml versus untreated.
doi:10.1371/journal.pone.0015572.g011
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the Dgcs1 cells have no GlcCer. Of note, the Dcap59 strain showed
a baseline reduction in the ability to exclude SYTOX when
compared to the wild type Cn. The capsule connection to the cell
wall may confer some additional stability to the cell surface in the
wild type that is not seen in the acapsular strain. Taken together,
these experiments shoed that Cz treatment of wild type Cn
recapitulates membrane deficits found in Dgcs1 strain.
Based on previous experiments reported here and the avirulent
phenotype of the Dgcs1 strain, we hypothesized that removal of
GlcCer by exogenous treatment with Cz would induce similar
deficits in wild type Cn, both in vitro and during infection. The in
vitro effects of Cz on Cn growth were then assessed. As shown, Cz
treatment reduced the growth of Cn at high CO2 but not at low
CO2, most notably at 48 hours of growth. At 24 hours of growth,
there were little differences in the treated and untreated groups
during incubation at high CO2. This is not entirely unexpected, as
the growth defects in the Dgcs1 strain itself (with no GlcCer at all)
only first start to appear at 24 hours of growth. This finding is
significant, as Cz treatment should theoretically recapitulate the
Dgcs1 phenotype, as shown above with membrane integrity
experiments. This pattern of growth inhibition with Cz treatment
is consistent with the Dgcs1 phenotype, which shows growth
differences compared to wild type Cn at high but not low CO2.
We hypothesized that treatment of infected mice would reduce
the growth of Cn in the extracellular spaces of the lung, and
prolong host survival. Infected mice were treated with two
different doses of Cz, and survival was compared to vehicle
control. The higher dose of Cz showed significant increase in
length of survival time in the treated mice. We further speculate
that the Cz-mediated reduction in extracellular growth in the lung
allowed the mouse immune system to delay the eventual
dissemination of Cn, increasing the time to mortality. To assess
this, additional experiments are needed to examine the physio-
pathology of the lung infection in treated and untreated animals.
Cz treatment did not prove curative or completely protective
against the infection, as all mice tested eventually died. This could
be due to the fact that the optimal activity of Cz is at more acidic
pH than that found in the extracellular spaces of the lung, or that
Cz tends to accumulate in the phagolysosomes, where GlcCer
hydrolysis would have no effect (even Dgcs1 can grow at pH 4.0).
Another potential for Cz use is as an adjunct therapy in instances
of resistance or unmanageable side effects with standard antifungal
drugs (e.g. fluconazole). This hypothesis is supported by our
preliminary investigations in which the combination of Cz and
fluconazole has a strong synergistic effect against Cn in vitro and by
recent studies in C. albican in which alteration of GlcCer synthesis
renders the fungus hypersensitive to fluconazole [30].
The major findings of this study are illustrated in a schematic
form in Figure 14. This study showed that targeting the GlcCer
system in general has clinical significance. Though currently no
fungal Gcs1 inhibitors exist, targeting the enzyme directly in a
fungus-specific manner would be theoretically effective, and this
study provides justification for the development of such com-
pounds. Also, further dissecting the role of enzymes upstream in
the sphingolipid pathway leading to GlcCer synthesis could yield
even more therapeutic targets based on the same rationale used to
study Cz here.
Materials and Methods
Ethics Statement
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Figure 12. Cerezyme treatment decreases fungal GlcCer in mouse models of Cn infection. Mass spectrometry analysis of GlcCer of Cn
recovered from the lung of infected mice for 24 (A) or 48 (B) hours. Enzyme treatment hydrolyzed GlcCer in a dose-dependent manner. *, P,0.05 by
Student t test, 24 or 48 hours 20 U/Kg or 30 U/Kg of Cerezyme versus untreated.
doi:10.1371/journal.pone.0015572.g012
Figure 13. Cerezyme treatment in mouse models of infection
with Cn. CBA/J mice (n = 10 per group) were infected with 56105 Cn
wild type H99 strain intranasally. Mice were treated with PBS, 20 U/kg
or 40 U/kg of Cerezyme (Cz) immediately after the injection of fungal
cells and every 2 days. The higher dose of Cz conveyed a protective
effect to infected mice, showing a significant increase in survival (by
Wilcoxon-Rank Sum test P,0.01, compared to PBS treated mice). The
data are representative of two separate experiments.
doi:10.1371/journal.pone.0015572.g013
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Laboratory Animals of the National Institutes of Health. The
protocol was approved by the Medical University of South
Carolina Institutional Animal Care and Use Committee (Permit
Number: 2019). All animal procedures were performed according
to the approved protocol, and all efforts were made to minimize
suffering.
Strains and media
The strains used in this study were wild type Cryptococcus
neoformans (Cn) H99 strain and the Dgcs1 mutant, which was created
in our laboratory [18]. Saccharomyces cerevisiae strains expressing
human GCS under a galactose-inducible promoter were used for
the in vitro enzyme activity of the human enzyme and were created
previously in our lab [18]. All strains were grown in YNB (yeast
nitrogen broth, Sigma-Aldrich) with 2% glucose and 50 mM
HEPES as a buffer, at either pH 4.0 or 7.2, as indicated. All
strains were grown at 37uC for all assays reported.
In vitro GCS assay
The in vitro GCS assay reported here was adapted from a
previous GCS assay in the fungus Pichia pastoris [27]. Briefly, this
assay used bead-disruption to lyse Cn cells and ultracentrifugation
(100,0006g for 30 min) to separate the lipid/membrane fraction
from the rest of the cell components. This membrane fraction is
used as the source of GCS enzyme in this assay, as purified fungal
GCS is not yet available. The 0.75 mg of membrane fraction is
suspended in reaction buffer (100 mM Tris/HCl, pH 8.0, 15%
glycerol). Radiolabeled UDP-Glucose (C14) was purchased from
American Radiolabeled Chemicals and 500,000 dpm was added
(10 GBq/mmol, final concentration 8 mM). To this, R-a-OH-
C16-ceramide from MUSC Lipidomics Core was added for a final
concentration of 0.3 mM. Triton X 100 was added for a final
percentage of 0.5% in a final volume of 100 mL. The mixture was
vortexed and sonicated for 30 second cycles, then incubated at
37uC for 45 minutes. At the end, 0.9 mL of 0.45% NaCl solution
was added, as well as 4 mL of chloroform:methanol 2:1 to stop the
reaction and achieve phase separation. A portion (1/4) of the
extracted lipids from the lower, organic phase of the extraction
were set aside for inorganic phosphate determination (Pi). Lipids
were then dried down in an SPD 2010 Speedvac (Thermo
Electron Corp.) and suspended in 50 mL of chloroform:methanol
2:1. Samples were then run on a thin layer chromatography (TLC)
plate along with a soy GlcCer standard for identification. The tank
solvent system used was chloroform: methanol: water in the ratio
97.5: 7.5:6. Sugars were identified by using a resorcinol spray and
the plate was exposed to radiosensitive film for 2 days at 280uC.
Quantification was achieved by scraping the bands and running
samples in an LS 6500 scintillation counter (Beckman Coulter).
Values were normalized to Pi values.
In vivo GlcCer production and degradation assay
For the in vivo production assay, Cn cells were grown in the
media/growth conditions and time points. Radiolabeled palmitate
(2 mCi/mL) from American Radiolabeled Chemicals was added to
the media and cells. After 2 hours of incubation with the
radiolabeled palmitate, the cells were pelleted and the lipids were
extracted directly using the methods described below. After the
Mandala extraction protocol (described below), base hydrolysis
was performed on the lipids to remove most glycerolipids. Briefly,
lipids were suspended in 1 mL of chloroform and incubated with
0.5 mM sodium methoxide (in methanol) for 1 hour at 45uC.
After this, samples were centrifuged for 5 minutes at 3,000 rpm to
achieve phase separation. The lipid extraction, drying, and TLC
analysis was performed as above.
For the degradation assay, a pulse of radiolabeled palmitate was
added to the culture and incubated for 2 hours. Cells were
centrifuged and washed 5 times to remove external radiolabeled
palmitate. Cells were then suspended and allowed to grow until
the desired time points, then the lipids were extracted as described
above.
Figure 14. Schematic of GlcCer localization during infection and the proposed effect of GlcCer reduction in Cerezyme treatment or
Dgcs1 strain.
doi:10.1371/journal.pone.0015572.g014
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Production of IgM monoclonal antibodies against fungal
GlcCer
Anti-GlcCer IgM monoclonal antibodies (mAb) were generated
as follow: three Balb/c mice were infected with 103 Cn H99 wild-
type cells. At 14, 21, and 28 days post-infection, blood was
collected from the saphenous vein, serum obtained and examined
for the presence of IgM against Cn GlcCer using an ELISA (see
below). As a negative control, three mice were infected with 103 Cn
Dgcs1 cells and at day 14, 21, and 28 serum was obtained and used
in the ELISA. IgM antibodies against Cn GlcCer were detected in
mice infected with Cn wild-type but not in mice infected with Cn
Dgcs1 (Figure S3). Therefore, at day 29, mice infected with Cn
wild-type H99 were sacrificed, spleenocytes were isolated and
fused to SP2/0 myeloma cells using polyethylene glycol 1500
(Roche Applied Science, Penzberg, Germany). The resulting cells
were plated onto 96-well plates and selected with hypoxanthine-
aminopterine-thymidine medium (Invitrogen, San Diego, CA). At
10 days post fusion, the supernatant of hybridoma cells was
screened by ELISA against soy GlcCer obtained from Avanti
Polar Lipids. Soy instead of Cn GlcCer was used for screening the
hybridoma supernatants because of the commercial availability of
the plant sphingolipid and because a previously made IgG
monoclonal antibody against fungal GlcCer (MEST-2) also cross
reacted against soy GlcCer [31]. Thus, we reasoned that an IgM
against Cn GlcCer would also cross react against the soy
sphingolipid. Positive clones were screened three times by limited
dilutions and re-examined by ELISA. The positive clones were
then amplified and stored in liquid nitrogen. The determination of
the antibody isotyping was performed by using a Roche isostrip
test following the method recommended by the manufacturer. We
isolated two IgM clones: F09 and B11 mAb, which were examined
for reactivity against purified GlcCer obtained from Cn cells. IgM-
B11 contains a kappa light chain whereas IgM-F09 contains a
lambda light chain. F09 and B11 were further purified according
to previously described methods [32]. The concentration of each
mAb obtained was determined using Bio-Rad protein assay.
ELISA
ELISA was performed by coating 96 well plates (Nunc
maxisorp) with 5 mg GlcCer, which was obtained as follow: soy
GlcCer was from Avanti (Avanti 131304P), Cn and Ca GlcCer
were purified from Cn wild-type strain H99 and Ca wild-type strain
A39, respectively; mouse GlcCer was extracted from mouse
peritoneal macrophage cell line J774.16. GlcCer was isolated and
purified from fungi or mammalian cells following a protocol
previously described [15]. Galactosylceramide (GalCer was
obtained from Avanti (KRN7000). Other lipids described in
Figure 1 were obtained from the MUSC Lipidomic core facility.
The lipid-coated plates were dried overnight. The plates were then
blocked with 5% BSA in phosphate buffered saline (PBS) for
1 hour at 37uC and then washed three times with 0.1% PBS-
Tween 20. One hundred ml of supernatant containing 50 ml of
mouse serum or hybridoma supernatant (diluted at 1:24 with PBS)
were added and the plates were incubated 1 hour at 37uC
followed by three washes with 0.1% PBS-Tween 20. For F09 or
B11, 50 ml of 1:64 dilution of 1 mg/ml was used. Peroxidase-
conjugated secondary anti-mouse IgM antibody (Sigma A786)
diluted 1:30,000 was added and the plates incubated for 1 hour at
37uC. Following 3 washes with 0.1% PBS-Tween 20, color
development was observed using 3,39,5,59 tetramethylbenzidine
substrate (TMB) (Sigma T0440). The reaction was stopped by the
addition of 1N HCL and optical density was measured at 450 nm
and recorded. As a negative control, the secondary antibody anti-
IgM was used alone.
Immunofluorescence
Cells were grown in the appropriate conditions described.
After this, 2.5 mL 5x fixation reagent (46 mL of 0.5 M potassium
phosphate and 54 mL of formaldehyde) was added to 10 mL
cultures of cells. After 2 hours of shaking, the cells were
centrifuged at 500xg for 5 minutes at room temperature to
pellet. The cells were then suspended in 1x fixation reagent and
allowed to incubate, shaking, overnight in the fixative. After this,
the cells were centrifuged for 500xg for 5 minutes to pellet. The
cells were then suspended in 0.5 mL of SHA buffer (1 M sorbitol,
100 mM HEPES, 50 mM sodium azide in H2O, final pH 7.5).
After washing twice with SHA 1 mL of buffer, 103 cells were
suspended in 0.5 mL of WT buffer (100 mM HEPES, 0.3 M
NaCl, 2 mM sodium azide, 10 g bovine serum albumin, 0.2 mL
of Tween in 200 mL H20 total) with 8 mg/mL of monoclonal
anti-Cn GlcCer antibody, and incubated with shaking at room
temperature overnight. Washed with 1 mL of WT buffer four
times and suspended in WT buffer with FITC-conjugated goat
anti-mouse IgM secondary antibody. Incubate shaking at room
temperature for one hour. Wash with 1 mL of WT buffer four
times and suspend in 50 mL of WT buffer. Then, 20 mL of cells
were added to glass slide coated with poly-L-lysine. ProLong
Gold Antifade Reagent (Invitrogen, 5 mL) was added and the
slides were given a coverslip and analyzed with confocal
microscopy.
Cz treatment in vitro
Cerezyme was provided generously by the Genzyme Corpora-
tion. For the in vitro assay, Cerezyme power was reconstituted with
sterile water. GlcCer extraction form Cn wild-type was performed
as previously described [18] and 8 mg of purified sphingolipid was
incubated with Cerezyme as indicated. After incubation for one
hour at 37uC, the sphingolipids were extracted by addition of an
equal volume of chloroform. The mixture was centrifuged and the
organic layer removed, dried, and added to a thin layer
chromatography (TLC) plate (Whatman). A soy GlcCer (Avanti
Polar Lipids) standard was loaded to identify the sphingolipid. The
plates were run in a tank with chloroform: methanol: water in the
ratio 97.5:37.5:6. The sphingolipids were visualized with a
resorcinol spray.
Animals survival studies and broncheoalveolar lavage
(BAL)
The mice used were female CBA/J (Jackson Laboratories), age
4–6 weeks. For the infection studies, mice were injected
intranasally with 56105 cells. After 20 minutes, mice were treated
with either PBS, 20 U/kg of Cerezyme (Cz) or 40 U/kg of Cz.
This treatment was then repeated every 48 hours and survival was
monitored. Broncheoalveolar lavage was performed as previously
described [33]. Cells were collected, mouse macrophages were
lysed by adding 0.05% SDS, and after 5 minutes the mixture was
centrifuged at 1000 g for 10 minutes. The pellet (Cn cells) was
suspended in 1 ml PBS and 100 ml was used for CFU whereas the
remaining 900 ml was used for lipid extraction.
Lipid Extraction and Analysis
Lipids were extracted as previously described [18,34]. The
Mandala extraction reagent is incubated with cells at 60uC with
intermediate vortexing and sonication. After centrifugation to
remove the debris, the reagent containing the lipids is dried down.
The dried lipids were submitted to MUSC Lipidomics Core
Facility for analysis and quantification with mass spectroscopy
using the purified Cn GlcCer as a standard.
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SYTOX assay
The assay was performed based on the specifications given in
previous publications using fungal membranes [35,36]. Briefly,
after growth in the media and treatment with Cerezyme (either 0,
200, or 400 units/mL, for one hour), 104 cells were suspended in
sterile PBS and transferred into a 96-well plate. SYTOX Green
dye (Invitrogen) was added to each well for a final concentration of
0.2 mM. The amount of fluorescent signal per well was measured
in a Wallac 1420 multilabel counter (Perkin Elmer) with an
excitation frequency of 485 nm and emission frequency of
535 nm.
Supporting Information
Figure S1 Expression of GCS1 transcript in Cn grown at
high (5%) compared to low (0.04%) CO2. Reverse
transcription-PCR (RT-PCR) was used with primers specific to
the GCS1 gene. Differences in GCS1 transcript level in wild type
(WT) Cn grown at high and low CO2 were the indistinguishable
using this technique. The positive control was Cn genomic DNA
(gDNA) as the PCR template instead of the transcript-derived
cDNA. Dgcs1 strain was used at the negative control, and the actin
expression was used as the normalization control.
(TIF)
Figure S2 Amount of GlcCer in wild type and acapsular
Cn grown in high CO2 and either acidic or neutral pH.
The total amount of GlcCer in wild type Cn (A) and an acapsular
strain of Cn, cap59 (B) grown from 16–72 hours was quantified
using mass spectrometry and normalized to inorganic phosphate
(Pi). Though cap59 had more GlcCer than the wild type overall,
there were no significant differences in GlcCer amount grown in
different pH.
(TIF)
Figure S3 IgM response in mice infected with C.
neoformans. IgM anti-GlcCer antibodies are found in serum
of mice infected with Cn wild type H99 but not in sera of mice
infected with Cn Dgcs1 mutant by Enzyme-linked immunosorbent
assay (ELISA).
(TIF)
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